Home - NX Development Corp

LATEST NEWS

2021 CNS Annual Meeting

Lexington, KY | October 25, 2021—NX Development Corp. exhibited at the 2021 Congress of Neurological Surgeons (CNS) Annual Meeting in Austin, TX. This meeting could be described as a complete success due to the high in-person attendance, numerous...

NX Development Corp. (NXDC) Receives FDA Orphan-Drug Designation for Gleolan® (aminolevulinic acid HCl) in Meningioma

Lexington, KY, Jan. 12, 2021 (GLOBE NEWSWIRE) — NX Development Corp. (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced FDA orphan-drug designation for Gleolan, an optical imaging agent for the...

NX DEVELOPMENT CORP. (NXDC) LAUNCHES GLEOLAN™ (AMINOLEVULINIC ACID HCL) MENINGIOMA PHASE III CLINICAL TRIAL (NXDC-MEN-301)

LEXINGTON, KY |GlobeNewswire| November 17, 2020 — NX Development Corp (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced the enrollment of the first patient in a Phase III multicenter study of Gleolan to...

Lexington-Based NX Development Corp (NXDC) Announces Baptist Health Lexington is First Hospital in Kentucky to Use Breakthrough Imaging Agent for Brain Tumor Visualization

Dr. Christian Ramsey first neurosurgeon in state to use Gleolan™ for enhanced visualization of high-grade gliomas/glioblastoma

AANS 2019

Lexington, KY | September 1, 2019 — NXDC was proud to be an exhibitor and supporter of the American Association of Neurological Surgeons Annual Scientific Meeting 2019 in San Diego, CA and we are already looking forward to AANS 2020 in...

NX Development Corp. (NXDC) Launches FDA-Approved Gleolan™ (aminolevulinic acid HCl) for Enhanced Visualization of High-Grade Gliomas (including Glioblastomas)

Lexington, Kentucky | October, 2018 — NX Development Corp. (NXDC), a life sciences company, today announced the U.S. commercial launch of its flagship product Gleolan™ (aminolevulinic acid HCl), the first and only FDA-approved optical imaging...